Companies /Healthcare

MeiraGTx Holdings plc

NASDAQ: MGTX Biotechnology
$8.32
▼ $0.14 (−1.65%) today
Markets closed · 7:04am ET

MGTX at a Glance

Valuation
Market cap
$813.1M
P/E ratio
9.6
Profitability
Revenue (TTM)
$401.9M
Profit margin
19.5%
EPS (TTM)
$0.87
Price
52-week range
$7 – $15
Street target
$27.75

Headquartered in New York, NY Fiscal year ends December NASDAQ: MGTX meiragtx.com

About MeiraGTx

MeiraGTx Holdings plc is a vertically integrated, clinical-stage genetic medicines company developing AAV-based gene therapies delivered locally in small doses.

Its pipeline includes four late-stage programs:
- Botaretigene sparoparvovec (bota-vec) for X-linked retinitis pigmentosa, reacquired in full from Johnson & Johnson in May 2026, with an EMA MAA planned for December 2026 and an FDA BLA for Q1 2027.
- AAV2-hAQP1 for radiation-induced xerostomia, which holds FDA Breakthrough Therapy Designation and is in a pivotal Phase 2 study.
- AAV-GAD for Parkinson's disease, which holds RMAT designation and is being advanced through the Reogen joint venture with Hologen.
- Ocular programs, including AAV-AIPL1 for LCA4, licensed to Eli Lilly for a $75 million upfront payment plus over $400 million in potential milestones and royalties.

The company also has a proprietary riboswitch gene regulation platform that controls in vivo production of biologics with oral small molecules. It is applying the platform to metabolic peptides (Ribo-Leptin, GLP-1, GIP, amylin, PYY), neuropathic pain, and cell therapy.

MeiraGTx runs end-to-end in-house manufacturing, including GMP viral vector facilities in London and a commercially licensed QC facility in Shannon, Ireland. It currently earns service revenue from contract manufacturing and development services for partners such as Lilly and Reogen. Updated

Latest Activity

MGTXMeiraGTx
Q3 2026
EPS
-$0.53
est -$0.47-12.0%
Revenue
$5M
est $7M-31.5%

The miss on both lines is pre-launch spending showing up early: R&D climbed to $39.3 million as MeiraGTx readies bota-vec filings, with the EMA dossier due in December and the FDA BLA in the first quarter of 2027. Cash of $184.7 million plus a $95 million Hologen payment funds operations into the second half of 2028, so the regulatory calendar matters more than this quarter.

Quarterly EPS — reported vs estimate

MGTX Coverage

Frequently Asked Questions

What does MeiraGTx do?

MeiraGTx Holdings plc is a vertically integrated, clinical-stage genetic medicines company developing AAV-based gene therapies delivered locally in small doses.

What is the MGTX stock price target?

The Wall Street consensus 12-month price target for MGTX is $27.75.